One-Pot Access to Indolo[2,3-b]quinolines by Electrophile-Triggered Cross-Amination/Friedel−Crafts Alkylation of Indoles with 1-(2- Tosylaminophenyl)ketones

Shaukat Ali,[†] Ying-Xiu Li,[†] Saeed Anwar,[‡] Fang Yang,[†] Zi-Sheng Chen,[†] and Yong-Min Liang^{*,†}

† State Key Laboratory of Applied Organic Chemistry, Lanzhou University, and State Key Laboratory of Solid Lubrica[tio](#page-6-0)n, Lanzhou Institute of Chemical Physics, Chinese Academy of Science, Lanzhou 730000, P.R. China

‡ Department of Chemistry, Abdul Wali Khan University, Mardan 23200, Pakistan

S Supporting Information

ABSTRACT: Activation of C2 and C3 of indoles by molecular iodine (I_2) and base followed by in situ reaction with 1-(2-tosylaminophenyl)ketones or 2-tosylaminobenzaldehyde can afford highly substituted indolo $(2,3-b)$ quinolines in moderate to excellent yields (up to 99%). The reaction provides a metalfree selective difunctionalization of indoles. The synthetic potential of the protocol has been illustrated by the synthesis of neocryptolepine and its 11-methyl analogue.

■ INTRODUCTION

Indoloquinolines have been well established to be useful as antibacterial, antifungal, antimalarial, anticancer, antiplatelet, aggregation, analgesic, antihypertensive agents as well as exhibiting several other activities.¹ It is believed that they act as DNA intercalating agents² and topoisomerase II inhibitors,³ and thereby one structure can ex[hib](#page-6-0)it an array of activities. The interesting biological activit[ie](#page-6-0)s of indoloquinolines (Figure 1[\)](#page-6-0) has stimulated the interest of synthetic chemists in developing new synthetic pathways to these polyheteroaromatic ri[ng](#page-1-0) systems.^{4−9} However, most of these syntheses suffer from lack of substrate generality, use of metal catalysts, and/or involve [two](#page-6-0) or more steps with exhaustive isolation/purification efforts resulting in low overall yields and hence of little interest to the pharmaceutical industry. Very recently, Seidel's group reported an excellent methodology for neocryptolepines and analogues.^{10,11} This reaction is extremely efficient for preparing a variety of substituted neocryptolepines. It is, however, not possible t[o syn](#page-6-0)thesize 11-substituted neocryptolepines and 6H $indolo(2,3-b)$ quinolines by Seidel's method. In our laboratory, we were interested in exploring a more general method for a one-pot/cascade synthesis of indoloquinolines from readily available substrates. We have previously described a metal-free cascade synthesis of functionalized quinolines.12 In pursuit of a protocol for preparing functionalized quinolines with diverse pharmacological properties, we envisioned [th](#page-6-0)at the readily available indoles can be activated by iodonium to undergo cross-amination with 1-(2-tosylaminophenyl)ketones at position-2. Elimination of HI promoted by a suitable base would then leave position 3 again prone to electrophilic attack by the

keto group (see Schemes 1 and 3) . In this way a new sequential reaction could be developed to affect selective difunctionalization of indol[es.](#page-1-0) Here[in](#page-3-0), we report a metal-free cascade coupling of indoles with 1-(2-tosylaminophenyl) ketones affording indolo[2,3-b]quinolines and its application to the synthesis of neocryptolepine and 11-methylneocryptolepine natural products.

■ RESULTS AND DISCUSSION

Our study began with the coupling reaction of an equal amount of N-methylindole 1a with 2-(tosylamino)benzophenone 2a in the presence of 2.0 equiv of iodine (I_2) and 2.0 equiv of K_2CO_3 in acetonitrile at room temperature. After 6 h, an examination of the reaction mixture revealed 25% of the expected indolo[2,3-b]quinolines 3a, 60% of the cross-aminated product 4 and 15% recovery of the starting materials. This initial investigation showed that the cross-amination step was going well but the cyclization via Friedel−Crafts alkylation did not occur smoothly. Changing the amount of iodine or base was not successful. When the nature of the base was changed, Cs_2CO_3 was found to be best (Table 1, entry 2), but the cyclization step was only 30% complete along with 62% of the cross-aminated product 4 and 8% starting [m](#page-1-0)aterials. In order to promote the cyclization step a number of Lewis and Bronsted acids were screened. Of them only AlCl_3 , HCl and $\text{AlCl}_3/\text{TfOH}$ were found to promote the cyclization step (Table 1 entries 9, 10, and 13). Of course, we were interested to produce a

Received: October 6, 2011 Published: December 2, 2011

Scheme 1. Design of a One-Pot Access to Indolo(2,3 b)quinolines

metal-free protocol, and thus, the use of HCl for further screening was continued. By using excess of HCl as additive, a 70% yield of 3a was obtained with no cross-aminated product 4 but again conversion was not complete (Table 1 entry 10). Turning to stoichiometry of the reaction revealed that by using 1.5 equiv of indole 1a with respect to ketone 2a 3a was furnished in 83% yield (Table 1 entry 14), but there were still some traces of substrates. When the reaction was carried out

Table 1. Optimization of Reaction Conditions

at 90 °C, a complete disappearance of starting materials was observed, and the highest yield of 3a (88%) was obtained (Table 1 entry 15).

With the standard reaction conditions in hand, we then explored the scope and generality of the method. We first examined the use of different protecting groups for the indolic N-atom. A variety of protecting groups such as alkyl, benzyl, and allyl groups was well tolerated (Scheme 2, products 3a− 3c). However, in the case of a tosyl group and N-unsubstituted indoles we observed no reaction. We then ex[am](#page-2-0)ined the effect of substituents in the indole moiety of indolo $[2,3-b]$ quinolines (Scheme 2, products 3d−3i). In general, we found that the presence of substituents with different electronic and steric propertie[s i](#page-2-0)n various positions did not have a significant effect on the formation of the indoloquinolines; all provided good to excellent yields. Similarly, the change of substituents in the 2-(tosylamino)phenyl ketones upon the efficiency of indolo- $[2,3-b]$ quinolines formation (Scheme 2, products 3j and 3k) revealed no effect on the formation of the indoloquinolines. The structure of product 3j was also co[n](#page-2-0)firmed by single-crystal X-ray crystallography (see the Supporting Information for details). Afterward, we examined the influence of $R⁴$ in the starting ketones 2 on the outcom[e of the reaction and yield](#page-6-0)s of

	1a	О Ph ⁻ $\ddot{}$ TsHN 2a	Ph I_2 , base additive solvent, temp. 3a	O Ph ² $\frac{1}{15}$ 4	
entry	base	solvent	additive ^{<i>a</i>} (equiv)	temp (°C)	yield $(\%)^b$ 3a/4
$\mathbf{1}$	K_2CO_3	CH ₃ CN		rt	25/60
2	Cs ₂ CO ₃	CH ₃ CN		rt	30/62
3	K_3PO_4	CH ₃ CN		rt	7/10
4	Cs ₂ CO ₃	CH ₃ OH		rt	6/40
5	Cs ₂ CO ₃	DMF		rt	traces
6	Cs_2CO_3	DCM		rt	10/30
7	Cs_2CO_3	CH ₃ CN		90	32/63
8	Cs ₂ CO ₃	CH ₃ OH		70	6/45
9	Cs ₂ CO ₃	CH ₃ CN	AlCl ₃ (2)	rt	$65/-$
$10\,$	Cs ₂ CO ₃	CH ₃ CN	HCI ^c	rt	$70/-$
11	Cs_2CO_3	CH ₃ CN	TfOH(0.1)	$^{\rm rt}$	33/62
12	Cs_2CO_3	CH ₃ CN	$HSBF6$ (0.1)	rt	37/62
13	Cs ₂ CO ₃	CH ₃ CN	AlCl ₃ (0.5) / TfOH (0.1)	rt	$60/-$
14	Cs_2CO_3	CH ₃ CN	HCl^c	rt	$83/-^d$
15	Cs_2CO_3	CH ₃ CN	HCl ^c	90	$88/-d$
16^e	Cs ₂ CO ₃	CH ₃ CN	HCI ^c	90	$86/-$
17^f	Cs_2CO_3	CH ₃ CN	HCl^c	90	$84/-$

^a All reactions were run under the following conditions, unless otherwise indicated: 0.2 M 1a, 0.2 M 2a, 0.4 M I₂, and 0.4 M base in wet solvent. Additive was added to the reaction mixture at room temperature after 9 h and further stirred at room temperature for 6 h. ^bBased on isolation of products after column chromatography. ²250 μL (25 equiv) of 12 M HCl was used as additive. ⁴0.3 M **1a**, 0.6 M I₂ and 0.6 M base was used. ⁶0.61 M I_2 was used. $f_{0.59}$ M I_2 was used.

Scheme 2. Scope of Metal-Free Cross-Amination/Alkylation Cascade of Indoles with $1-(2$ -Tosylaminophenyl)ketones^{a,b,c}

^aAll reactions were run under the following conditions, unless otherwise indicated: 0.3 M 1, 0.2 M 2, 0.6 M I₂, and 0.6 M base in wet solvent for 9 h at 90 °C and then 250 μ L of 12 M HCl was added at room temperature and further stirred at room temperature for 6 h. The equiv of iodine and $Cs₂CO₃$ corresponds to 1. $bthTh$ exields are based on isolation of products after column chromatography. ^{*C*} After adding HCl the reaction was stirred $Cs₂CO₃$ corresponds to 1. $bthTh$ exi for 12 h.

the various 11-substituted indolo $[2,3-b]$ quinolines (Scheme 2, products 3l−3m and 3o−3q). With an electron-withdrawing group such as $4\text{-}ClC_6H_5$, we observed only 5% of the corresponding indolo[2,3-b]quinoline. However, $4-\text{BrC}_6\text{H}_5$ gave 90% yield of the corresponding indolo[2,3-b]quinoline (Scheme 2, product 3q), although Cl and Br differ only slightly in electronegativity. With a more electron-rich but rather bulky group such as $4\text{-}MeOC₆H₅$, the reaction time was increased to 21 h, and only 32% yield of the product was obtained. Also, when $3,4$ -Me₂C₆H₄ was used, only traces of product was generated. These findings show that the yields of products 3 are evidently susceptible to subtle changes in the nature of the C-11 substituent (or, correctly, R^4 in 2).

Knowing the importance of neocryptolepines as antimalarial and antitumor agents, we also investigated the reaction of 2 tosylaminobenzaldehyde 2f with N-methyl and N-benzyl indoles 1a and 1b under initially optimized conditions. The corresponding indolo $[2,3-b]$ quinolines 3r and 3s were obtained in moderate yields of 32% and 40% along with dialkylated products (or more properly 11-indolylindolo[2,3-b]quinolines) 5a and 5b in 63% and 52% yields, respectively. The dialkylated products were suppressed, and the yields of the desired products were improved by carrying out the reactions at room temperature with 3 equiv of the indole derivative (see Table 2).

The mechanism of this reaction involves electrophilic addition of iodonium to the 3-position of indole 1 to g[iv](#page-3-0)e

Table 2. Cross-Amination/Alkylation of N-Methyl Indole (1a) and N-Benzyl Indole (1b) with 2-Tosylaminobenzaldehyde $(2f)^{a,b}$

 a All reactions were run for 9 h, and then 250 μ L of 12 M HCl was added at room temperature and further stirred at room temperature for 6 h. The equiv of iodine and Cs_2CO_3 corresponds to 1. b The yields are based on isolation of products after column chromatography.

Scheme 3. Proposed Mechanism

cation A, which undergoes 2-amination with 2 to afford B. The intermediate B eliminates a molecule of HI in the presence of base to give 4. Alkylation and subsequent detosylation of 4 in the prescence of HCl gives 3. The formation of 11 indolylindolo[2,3-b]quinolines 5 can be explained as follows. When the intermediate carbocation C has a H-atom on the 11 position $(R^4 = H)$, due to less steric hindrance and more reactivity it is attacked by a second molecule of 1 to give D. Finally, D gains full aromaticity via oxidation by molecular iodine (I_2) or air^{13,14} to give 5 (see Scheme 3).

The application of the new annulation strategy to the synthesis of th[e](#page-6-0) [ne](#page-7-0)ocryptolepine, a linear 5-N-methyl-5H $indolo[2,3-b]$ quinoline alkaloid isolated from the West African shrub Cryptolepis sanguinolenta which has been reported to exhibit strong antiplasmodial activity,¹⁵ illustrates the utility of this methodology. 11-Methylneocryptolepine which has been found to display strong antimicrobial [an](#page-7-0)d cytotoxic activities in vitro and significant antitumor properties in vivo 16 can also be prepared by using our protocol. Products 3s and 3n were prepared on 10 mmol scale. To our delight; [th](#page-7-0)e reactions

proceeded without change in reaction yields. Debenzylation 17 with AlCl₃ in refluxing benzene and then regioselective methylation¹⁸ of quinoline N-atom with $Me₂SO₄$ afford[ed](#page-7-0) neocryptolepine 7a and 11-methylneocryptolepine 7b in overall 68% and 6[4%](#page-7-0) yields, respectively (Scheme 4).

■ CONCLUSION

In short, we have described a useful ann[u](#page-4-0)lation strategy of readily available indoles to indolo $(2,3-b)$ quinolines. The reaction is metal-free and can produce substituted indolo(2,3 b)quinolines in a one-pot manner. Our simple approach to $indolo(2,3-b)$ quinolines complements existing routes and allows access to some novel C-11-substituted derivatives. Synthesis of neocryptolepine and its various analogues can be carried out in overall moderate yields.

EXPERIMENTAL SECTION
General Methods Used for Preparing Starting Materials 1a-1i and 2a-2i. Starting materials 1a-1i were prepared by methylation, benzylation, or allylation of the corresponding indoles Scheme 4. Synthesis of Neocryptolepine and 11-Methylneocryptolepine

according to the literature procedure.¹⁹ Starting materials 2a−2i were prepared by tosylation of the corresponding 2-aminobenzoketones or 2-aminobenzaldehyde according to [th](#page-7-0)e literature procedure.^{20,21} 2-Aminobenzaldehyde was prepared by reduction of 2-nitrobenzaldehyde according to the literature procedure²² and used imm[ediate](#page-7-0)ly. The respective characterization data of all the starting materials match those reported in the literature.

General Procedure A. Preparation [of](#page-7-0) [I](#page-7-0)ndolo(2,3-b)quinolines $(3a-3s)$ and $(5a-5b)$. Iodine (152.4 mg, 2.0 equiv) was added to a solution of 1a (0.3 mmol, 39.3 mg), 2a (0.2 mmol, 70.2 mg) and $Cs₂CO₃$ (195.6 mg, 2.0 equiv) in acetonitrile (1.0 mL). The resulting mixture was stirred for 9 h at 90 °C. Then the reaction mixture was cooled to room temperature, and 250 μ L (25 equiv) of 12 M HCl was added, and the mixture further stirred at room temperature for 6 h. The reaction was then quenched by adding saturated aq solution of $Na₂S₂O₃$ and extracted with ethyl acetate (3 × 15 mL). The combined organic phases were washed with aq NaHCO₃ and brine, and dried over anhyd. Na₂SO₄. After removal of solvent the crude product was purified by column chromatography with silica gel using a mixture of petroleum ether (bp 40−80 °C) and ethyl acetate (20: 1) to give 54.5 mg of 3a (88%).

In case of $indolo(2,3-b)$ quinolines 3r and 3s the amount of indole 1b was 0.6 mmol, 124.3 mg, and the reaction was conducted at room temperature. The rest of procedure remains the same.

Characterization Data of Products (3a−3s) and (5a−5b). 6- Methyl-11-phenyl-6H-indolo[2,3-b]quinoline (3a): yield 88%; lightgreen solid; mp 152−154 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.17 $(H, d, J = 8.4 \text{ Hz})$, 7.68–7.74 (2H, m), 7.61–7.66 (3H, m), 7.52– 7.53 (2H, m), 7.45−7.51 (1H, m), 7.32−7.38 (2H, m), 7.05 (1H, d, $J = 7.6$ Hz), 6.96–7.00 (1H, m), 4.02 (3H, s); ¹³C NMR (CDCl₃, 100 MHz): δ 152.4, 146.8, 142.9, 142.3, 136.6, 129.8, 129.3, 128.9, 128.4, 127.7, 127.2, 126.3, 123.7, 123.0, 122.7, 120.5, 119.6, 115.9, 108.3, 27.7; IR (neat) ν: 3399, 3056, 2925, 2862, 1598, 1480, 1392, 1319, 1252, 1122, 1024, 746, 703 cm⁻¹; HRMS (ESI) calcd for C₂₂H₁₇N₂ $(M^+ + H)$: 309.1386, found: 309.1388.

6-Benzyl-11-phenyl-6H-indolo[2,3-b]quinoline (3b): yield 90%; light-yellow solid; mp 148–150 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.16 (1H, d, J = 8.4 Hz), 7.73 (1H, d, J = 8.0 Hz), 7.67–7.71 (1H, m), 7.61−7.64 (3H, m), 7.53 (2H, dd, J = 2.0, 7.6 Hz), 7.33−7.37 $(4H, m)$, 7.24–7.28 (3H, t, J = 6.4 Hz), 7.21–7.23 (1H, t, J = 4.0 Hz), 7.05 (1H, d, J = 7.6 Hz), 6.93- 6.97 (1H, t, J = 7.6 Hz), 5.79 (2H, s) ; ¹³C NMR (CDCl₃, 100 MHz): δ 152.2, 146.8, 142.3, 142.1, 137.3, 136.6, 129.3, 128.9, 128.6, 128.5, 127.8, 127.6, 127.3, 127.2, 126.4, 126.3, 124.0, 123.0, 122.8, 120.8, 119.8, 115.8, 109.3, 44.9; IR (neat) ν: 3664, 3394, 3070, 2922, 1595, 1464, 1404, 1320, 1120, 1068, 1025, 865, 751, 702, 614 cm⁻¹; HRMS (ESI) calcd for $C_{28}H_{21}N_2 (M^+ + H)$: 385.1699, found: 385.1697.

6-Allyl-11-phenyl-6H-indolo[2,3-b]quinoline $(3c)$: yield 81%; light-green solid; mp 100−102 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.15 (1H, d, J = 8.8 Hz), 7.67−7.74 (2H, m), 7.62−7.64 (3H, q, J = 5.2 Hz), 7.51−7.54 (2H, m), 7.41−7.45 (1H, m), 7.32−7.37 (2H, m), 7.05 (1H, d, J = 7.6 Hz), 6.96 (1H, t, J = 7.6 Hz), 6.06−6.15 (1H, m), 5.17 (4H, q, J = 5.2 Hz) ; ¹³C NMR (CDCl₃, 100 MHz): δ 151.8, 146.7, 142.3, 142.2, 136.6, 132.7, 129.3, 128.9, 128.6, 128.4, 127.7, 127.6, 123.0, 122.8, 120.7, 119.7, 116.8, 115.8, 109.2, 43.6, 31.9, 22.6; IR (neat) ν: 3393, 3059, 2923, 1594, 1473, 1403, 1357, 1324, 1259, 1215, 1180, 1154, 1120, 1068, 1027, 765, 742, 701, 663, 613 cm⁻¹; HRMS (ESI) calcd for $C_{24}H_{19}N_2$ (M⁺ + H): 335.1543, found: 335.1545.

6,10-Dimethyl-11-phenyl-6H-indolo[2,3-b]quinoline (3d): yield 86%; light green solid; mp 184–186 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.11 (1H, d, J = 8.0 Hz), 7.64–7.68 (1H, m), 7.49–7.55 (6H, m), 7.37 (1H, t, 7.6 Hz), 7.23−7.28 (2H, m), 6.84 (1H, d, J = 7.2 Hz), 4.02 (3H, s), 1.7 (3H, s) ; ¹³C NMR (CDCl₃, 100 MHz): δ 152.2, 145.8, 143.7, 142.5, 139.7, 135.5, 131.2, 128.6, 128.2, 127.8, 127.7, 127.2, 127.1, 124.2, 123.3, 122.4, 119.5, 117.3, 105.9, 27.7, 22.1; IR (neat) ν: 3395, 3053, 2925, 1579, 1464, 1446, 1383, 1307, 1248, 1155, 1108, 1066, 1026, 961, 754, 702 cm⁻¹; HRMS (ESI) calcd for $C_{23}H_{19}N_2$ (M⁺ + H): 323.1543, found: 323.1546.

6,9-Dimethyl-11-phenyl-6H-indolo[2,3-b]quinoline (3e): yield 99%; yellow solid; mp 108−110 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.16 (1H, d, J = 8.4 Hz), 7.67–7.73 (2H, m), 7.50–7.52 (2H, m), 7.31−7.35 (1H, m), 7.27 (2H, t, J = 1.2 Hz), 7.24 (1H, d, J = 4.8 Hz), 6.83 (1H, s), 3.99 (3H, s), 2.27 (3H, s); ¹³C NMR (CDCl₃, 100 MHz): δ 152.5, 146.6, 142.2, 141.0, 136.6, 130.8, 128.9, 128.6, 128.4, 128.3, 127.4, 126.3, 123.6, 123.2, 123.2, 122.6, 120.6, 115.9, 108.1, 27.7, 21.3; IR (neat) ν: 3398, 3060, 2922, 2851, 1634, 1596, 1567, 1484, 1447, 1385, 1332, 1295, 1252, 1164, 1119, 1068, 1020, 761, 703 cm⁻¹; HRMS (ESI) calcd for $C_{23}H_{19}N_2$ (M⁺ + H): 323.1543, found: 323.1550.

6,8-Dimethyl-11-phenyl-6H-indolo[2,3-b]quinoline (3f): yield 83%; light-yellow solid; mp 136−140 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.15 (1H, d, J = 8.4 Hz), 7.69 (2H, q, J = 8.4 Hz), 7.61–7.68 $(2H, m)$, 7.50 $(2H, q, J = 2.0 Hz)$, 7.31–7.40 $(2H, m)$, 6.92 $(1H, d, J =$ 8.0 Hz), 6.79 (1H, d, J = 8.0 Hz), 3.98 (3H, s), 2.5 (3H, s); ¹³C NMR $(CDCl₃, 100 MHz): \delta$ 152.6, 146.5, 143.3, 142.2, 141.4, 140.9, 138.3, 136.7, 129.8, 128.9, 127.2, 126.2, 124.9, 123.7, 122.6, 120.9, 118.1, 116.0, 108.8, 27.6, 22.2; IR (neat) ν: 3399, 3059, 2923, 2854, 1597, 1466, 1423, 1391, 1307, 1251, 1161, 1114, 1067, 1027, 765,703 cm⁻¹; HRMS (ESI) calcd for $C_{23}H_{19}N_2$ (M⁺ + H): 323.1543, found: 323.1547

6,7-Dimethyl-11-phenyl-6H-indolo[2,3-b]quinoline (3g): yield 97%; light-green solid; mp 196−200 °C; ¹ H NMR (CDCl3, 400 MHz): δ 8.14 (1H, d, J = 8.4 Hz), 7.67 (2H, t, J = 4.0 Hz), 7.60 (3H, d, $J = 6.8$ Hz), 7.47 (2H, d, $J = 8.0$ Hz), 7.30 (1H, t, $J = 7.2$ Hz), 7.15 $(1H, d, J = 6.8 \text{ Hz})$, 6.81 $(2H, m)$, 4.32 $(3H, s)$, 2.85 $(3H, s)$; ¹³C NMR (CDCl₃, 100 MHz): δ 152.8, 146.6, 141.9, 136.7, 130.9, 129.3, 128.5, 127.5, 126.3, 124.8, 123.9, 122.6, 121.2, 121.0, 120.4, 119.6, 118.2, 115.7, 102.2, 29.3, 22.6; IR (neat) ν: 3400, 3046, 2923, 2854, 1607, 1580, 1492, 1459, 1389, 1297, 1222, 1163, 1131, 1080, 1025,

The Journal of Organic Chemistry **Article Article Article Article Article Article Article Article Article**

771, 745, 704, 403 cm⁻¹; HRMS (ESI) calcd for $C_{23}H_{19}N_2$ (M⁺ + H): 323.1543, found: 323.1548

9-Bromo-6-methyl-11-phenyl-6H-indolo[2,3-b]quinoline (3h): yield 85%; light-green solid; mp 180−184 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.13 (1H, \ddot{d} , J = 8.4 Hz), 7.67–7.72 (2H, m), 7.62–7.65 (3H, m), 7.50 $(1H, dd, J = 2.0, 8.8 Hz), 7.45–7.47(2H, m), 7.31–7.35 (1H, m), 7.16$ $(H, d, J = 8.4 \text{ Hz})$, 7.09 (1H, s), 3.94 (3H, s); ¹³C NMR (CDCl₃, 100 MHz): δ 152.1, 147.0, 142.9, 141.4, 135.8, 130.2, 129.2, 129.1, 129.0, 128.8, 127.6, 126.4, 125.5, 123.6, 123.0, 122.1, 114.8, 112.2, 109.7, 27.7; IR (neat) ν: 3397, 3062, 2922, 2840, 1626, 1585, 1477, 1442, 1383, 1330, 1278, 1122, 1069, 1027, 765, 767, 711, 613, 402 cm[−]¹ ; HRMS (ESI) calcd for $C_{22}H_{16}N_2Br(M^+ + H)$: 387.0491, found: 387.0497.

9-Methoxy-6-methyl-11-phenyl-6H-indolo[2,3-b]quinoline (3i): yield 86%; yellow solid; mp 152–154 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.14 (1H, d, J = 8.4 Hz), 7.66–7.74 (2H, m), 7.59–7.64 (3H, m), 7.50−7.52 (2H, m), 7.30−7.34 (1H, m), 7.22 (1H, d, J = 8.4 Hz), 7.05 $(1H, dd, J = 2.4, 8.8 Hz), 6.54 (1H, s), 3.96 (3H, s), 3.57 (3H, s); ¹³C$ NMR (CDCl₃, 100 MHz): δ 153.6, 152.6, 146.8, 142.2, 137.5, 136.4, 130.8, 129.4, 128.6, 128.4, 128.2, 127.5, 126.3, 123.3, 122.5, 120.8, 115.9, 108.8, 107.0, 55.5, 27.7; IR (neat) ν: 3393, 3058, 2923, 2854, 1594, 1483, 1386, 1331, 1289, 1263, 1223, 1118, 1067, 1029, 801, 769, 703, 653, 614, 402 cm⁻¹; HRMS (ESI) calcd for $C_{23}H_{19}ON_2 (M^+ + H)$: 339.1492, found: 339.1498.

2-Chloro-6-methyl-11-phenyl-6H-indolo[2,3-b]quinoline (3j): yield 80%; light-green solid; mp 260−263 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.07 (1H, d, J = 9.2 Hz), 7.59–7.67 (5H, m), 7.36 (1H, d, J = 8.4 Hz), $6.98-7.05$ (2H, m) 3.99 (3H, s); ¹³C NMR (CDCl₃, 100 MHz): δ 152.4, 145.1, 143.0, 141.3, 135.9, 129.4, 129.3, 129.2, 129.1, 128.7, 128.2, 128.1, 124.9, 124.3, 123.2, 120.2, 119.9, 116.5, 108.5, 27.6; IR (neat) ν: 3400, 3047, 2918, 2849, 2279, 1595, 1466, 1443, 1387, 1340, 1308, 1118, 1070, 1025, 812, 772, 735, 708, 403 cm[−]¹ ; HRMS (ESI) calcd for $C_{22}H_{16}N_2Cl$ (M⁺ + H): 343.0997, found: 343.1003.

2-Bromo-6-methyl-11-phenyl-6H-indolo[2,3-b]quinoline (3k): yield 82%; yellow solid; mp 248−251 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.01 (1H, d, J = 9.2 Hz), 7.83 (1H, s), 7.72 (1H, dd, 2, 8.8 Hz), 7.64 $(3H, t, J = 5.6 Hz)$, 7.37 (1H, d, J = 8 Hz) 6.98–7.04 (2H, m), 3.99 $(3H, s)$; ¹³C NMR (CDCl₃, 100 MHz): δ 152.4, 145.3, 143.0, 141.3, 135.8, 131.8, 129.3, 129.1, 128.8, 128.5, 128.3, 128.2, 128.1, 127.2, 120.2, 119.9, 116.5, 116.1, 108.5, 27.7; IR (neat) ν: 3794, 3664, 3407, 3053, 2921, 2851, 1060, 1463, 1443, 1385, 1309, 1220, 1158, 1110, 1066, 1023, 771, 738, 705 cm⁻¹; HRMS (ESI) calcd for $C_{22}H_{16}N_2Br$ $(M^+ + H)$: 387.0491, found: 387.0497.

6,11-Dimethyl-6H-indolo[2,3-b]quinoline (3l): yield 83%; yellow solid; mp 96−98 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.27 (1H, d, J = 8 Hz), 8.23 (1H, dd, J = 0.8, 8.4 Hz)), 8.12 (1H, d, J = 8.8 Hz), 7.69– 7.73 (1H, m), 7.55−7.60 (1H, m), 7.46−7.50 (1H, m) 7.41 (1H, d, J = 8 Hz), 7.30−7.34 (1H, m), 3.98 (3H, s), 3.19 (3H, s) ; ¹³C NMR (CDCl3, 100 MHz): δ 152.4, 146.7, 145.0, 142.7, 128.5, 128.1, 127.3, 123.6, 123.3, 122.9, 122.6, 120.7, 119.9, 115.3, 108.5, 27.6, 15.1; IR (neat) ν: 3399, 3060, 2852, 2245, 1685, 1626, 1602, 1578, 1472, 1430, 1390, 1319, 1285, 1245, 1120, 1089, 1065, 1025, 747, 403 cm⁻¹; HRMS (ESI) calcd for $C_{17}H_{15}N_2$ (M⁺ + H): 247.1230, found: 247.1236.

11-Ethyl-6-methyl-6H-indolo[2,3-b]quinoline (3m): yield 85%; yellow solid; mp 126−130 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.19−8.25 (2H, m), 8.13 (1H, d, J = 8.4 Hz), 7.68−7.73 (1H, m), 7.54−7.59 (1H, m), 7.45−7.49 (1H, m), 7.40 (1H, d, J = 8 Hz), 7.29− 7.33 (1H, m), 3.97 (3H, s), 3.63 (2H, q, J = 7.6 Hz), 1.51 (3H, t, J = 7.6 Hz) ; 13C NMR (CDCl3, 100 MHz): δ 152.4, 146.7, 145.0, 142.7, 128.5, 128.1, 127.3, 123.6, 123.3, 122.9, 122.6, 120.7, 119.9, 115.3, 108.5, 27.6, 22.1, 13.6; IR (neat) ν: 3664, 3398, 3060, 2963, 2923, 2851, 1626, 1601, 1567, 1473, 1428, 1393, 1319, 1275, 1245, 1121, 1057, 1024, 748, 402 cm⁻¹; HRMS (ESI) calcd for C₁₈H₁₇N₂ (M⁺ + H): 261.1386, found: 261.1380.

6-Benzyl-11-methyl-6H-indolo[2,3-b]quinoline (3n): yield 81%; light-green solid; mp 144−147 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.10 (1H, dd, J = 0.8, 8.4 Hz), 7.67−7.71 (1H, m), 7.41−7.49 (2H, m), 7.20−7.30 (3H, m), 5.71 (2H, s), 3.18 (3H, s) ; 13C NMR (CDCl3, 100 MHz): δ 152.1, 146.6, 144.1, 141.9, 138.9, 137.0, 128.2, 127.1, 126.4, 124.3, 123.5, 122.6, 121.6, 120.1, 119.9, 118.9, 116.2,

109.6, 109.4, 44.7, 15.1; IR (neat) ν: 3395, 3060, 2923, 2854, 1722, 1621, 1602, 1577, 1471, 1404, 1379, 1321, 1286, 1263, 1213, 1153, 1122, 1072, 745, 702, 462 cm⁻¹; HRMS (ESI) calcd for C₂₃H₁₉N₂ $(M^+ + H)$: 323.1543, found: 323.1539.

11-(4-Bromophenyl)-6-methyl-6H-indolo[2,3-b]quinoline (3o): yield 90%; light-green solid; mp 156−160 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.16 (1H, d, J = 8.4 Hz), 7.77 (2H, d, J = 8.4 Hz), 7.66–7.70 $(2H, m)$, 7.47–7.52 (1H, m), 7.37 (4H, q, J = 8.4 Hz), 7.10 (1H, d, J = 7.6 Hz), 7.01–7.05 (1H, m), 4.00 (3H, s) ; ¹³C NMR (CDCl₃, 100 MHz): δ 152.2, 146.7, 142.9, 140.7, 135.5, 132.2, 132.5, 131.1, 129.6, 128.7, 127.7, 127.2, 125.9, 123.3, 122.8, 120.2, 119.8, 115.8, 108.5, 27.6; IR (neat) ν: 3732, 3393, 2922, 2857, 1591, 1455, 1429, 1387, 1156, 1107, 1065, 1025, 826, 767, 717, 582 cm[−]¹ ; HRMS (ESI) calcd for $C_{22}H_{16}N_2Br(M^+ + H)$: 387.0491, found: 387.0486.

6-Methyl-11-(p-tolyl)-6H-indolo[2,3-b]quinoline $(3p)$: yield 86%; light-green solid; mp 119−121 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.16−8.18 (1H, m), 7.75 (1H, dd, J = 0.8, 8.4 Hz), 7.67−7.71 (1H, m), 7.32−7.50 (7H, m), 7.13 (1H, d, J = 8.0 Hz), 6.98−7.02 (1H, m), 4.01 (3H, s), 2.56 (3H, s); ¹³C NMR (CDCl₃, 100 MHz): δ 152.4, 146.8, 142.9, 142.5, 138.2, 133.4, 129.6, 129.2, 128.6, 127.6, 127.5, 126.4, 123.9, 123.0, 122.6, 120.7, 119.6, 116.0, 108.3, 27.6, 21.5; IR (neat) ν: 3403, 3057, 2923, 2862, 1592, 1479, 1429, 1392, 1322, 1251, 1160, 1119, 1068, 1027, 818, 755, 634 cm[−]¹ ; HRMS (ESI) calcd for $C_{23}H_{19}N_2$ (M⁺ + H): 323.1543, found: 323.1547.

11-(4-Methoxyphenyl)-6-methyl-6H-indolo[2,3-b]quinoline (3q): yield 32%; yellow solid; mp 90–92 °C; ¹H NMR (CDCl₃, 400 MHz): δ 7.68 (1H, d, J = 8.0 Hz), 7.64 (1H, d, J = 7.6 Hz), 7.35 (2H, t, J = 8.4 Hz), 7.28−7.32 (3H, m), 7.20−7.24 (2H, m), 7.17−7.19 (2H, m), 7.11−7.15 (1H, m), 6.61 (1H, brs), 3.86 (3H, s), 3.74 (3H, s) ; ¹³C NMR (CDCl₃, 100 MHz): δ 142.0, 137.9, 136.9, 135.0, 130.1, 128.3, 127.6, 122.3, 120.9, 120.3, 120.1, 119.9, 119.5, 116.1, 115.9, 109.4, 109.3, 107.3, 101.3, 22.6, 14.1; IR (neat) ν: 3733, 3402, 3049, 2923, 2855, 1583, 1461, 1382, 1320, 1243, 1071, 1023, 743, 667, 571 cm[−]¹ ; HRMS (ESI) calcd for $C_{23}H_{19}ON_2$ (M⁺ + H): 339.1492, found: 339.1497.

6-Methyl-6H-indolo[2,3-b]quinoline (3r): yield 71%; light-green solid; mp 42−45 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.67 (1H, s), 8.11 (2H, q, J = 4.4 Hz), 7.9 (1H, d, J = 8 Hz), 7.69 (1H, t, J = 7.6 Hz), 7.55 (1H, t, J = 7.6 Hz), 7.42 (1H, t, J = 7.6 Hz), 7.38 (1H, d, J = 8.0 Hz), 7.27 (1H, t, J = 7.2 Hz), 3.97 (3H, s); ¹³C NMR (CDCl₃, 100 MHz): δ 152.7, 146.7, 142.8, 128.8, 128.5, 128.0, 127.4, 127.3, 124.1, 122.8, 121.4, 120.4, 119.9, 118.2, 108.7, 27.7; IR (neat) ν: 3401, 3054, 2924, 2856, 1606, 1573, 1481, 1431, 1395, 1362, 1321, 1254, 1148, 1118, 779, 743 cm⁻¹; HRMS (ESI) calcd for C₁₆H₁₃N₂ (M⁺ + H): 233.1073, found: 233.1075.

6-Benzyl-6H-indolo[2,3-b]quinoline (3s): yield 78%; white solid; mp 160−163 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.74 (1H, s), 8.12 $(2H, t, J = 8.4 \text{ Hz})$, 8.00 (1H, d, J = 7.2 Hz), 7.68–7.73 (1H, m), 7.44−7.48 (2H, m), 7.22−7.36 (H, m), 5.76 (2H, s) ; 13C NMR (CDCl3, 100 MHz): δ 142.06, 137.3, 136.7, 128.6, 128.0, 127.7, 127.0, 126.9, 125.1, 123.3, 122.6, 122.5, 121.1, 120.8, 120.3, 119.6, 117.1, 110.1, 109.1, 50.4; IR (neat) ν: 3390, 2918, 1604, 1570, 1470, 1408, 1382, 1262, 1205, 1146, 1066, 1024, 737, 702 cm[−]¹ ; HRMS (ESI) calcd for $C_{22}H_{17}N_2$ (M⁺ + H): 309.1386, found: 309.1388.

6-Methyl-11-(1-methyl-1H-indol-3-yl)-6H-indolo[2,3-b]quinoline (5a): yield 73%; yellow solid; mp 230–233 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.18 (1H, d, J = 8.4 Hz), 7.99 (1H, dd, J = 1.2, 8.4 Hz), 7.67−7.71 (1H, m), 7.52 (1H, d, J = 8.4 Hz), 7.42−7.46 (1H, m), 7.29−7.38 (5H, m), 7.16 (2H, t, J = 8.8 Hz), 7.03 (1H, t, J = 7.2 Hz), 6.88−6.92 (1H, m), 4.04 (3H, s), 4.01 (3H, s) ; 13C NMR (CDCl3, 100 MHz): δ 152.7, 146.8, 142.8, 137.1, 135.9, 128.6, 127.6, 127.5, 127.4, 126.9, 124.9, 123.4, 122.4, 122.3, 120.9, 120.7, 120.0, 119.4, 117.1, 110.1, 109.9, 109.6, 108.1, 33.2, 27.7; IR (neat) ν: 3413, 3058, 2923, 2856, 1586, 1556, 1468, 1430, 1390, 1321, 1246, 1214, 1157, 1118, 1073, 1023, 752, 666 cm⁻¹; HRMS (ESI) calcd for C₂₅H₂₀N₃ $(M^+ + H)$: 362.1652, found: 362.1658.

6-Benzyl-11-(1-benzyl-1H-indol-3-yl)-6H-indolo[2,3-b]quinoline (5b): yield 52%; light-green solid; mp 110−112 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.18 (1H, d, J = 8.4 Hz), 7.99 (1H, d, J = 8.4 Hz), 7.67 $(1H, t, J = 7.2 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.43 (1H, s), 7.20–7.37$ $(16H, m)$, 7.04 $(1H, t, J = 7.6 Hz)$, 6.81 $(1H, t, J = 7.6 Hz)$, 5.74 $(2H,$ q, $J = 16$ Hz), 5.43 (2H, q, $J = 16$ Hz); ¹³C NMR (CDCl₃, 100 MHz): δ 152.4, 146.9, 142.0, 137.4, 137.4, 137.3, 136.7, 128.9, 128.6, 128.0, 127.9, 127.8, 127.7, 127.4, 127.2, 127.0, 126.9, 125.1, 123.3, 122.6, 122.5, 121.1, 120.8, 120.3, 119.6, 117.1, 110.7, 110.1, 109.1, 50.4, 44.9; IR (neat) ν: 3394, 3058, 2922, 2857, 1598, 1542, 1461, 1393, 1320, 1254, 1158, 1067, 1023, 916, 752, 663, 602 cm[−]¹ ; HRMS (ESI) calcd for $C_{37}H_{28}N_3$ (M⁺ + H): 514.2278, found: 514.2280.

General Procedure for Preparing 6H-Indolo[2,3-b] quinolines, 6a and 6b. Anhydrous $AICI_3$ (754.3 mg, 5.65 equiv) was added to a solution of 3s (1 mmol, 308 mg) in dry benzene (10.0 mL) and then refluxed for 9 h. On completion, 30 mL of 0.15 M HCl was added and extracted with ethyl acetate. The combined organic phases were washed with aq NaHCO₃ and brine and were dried over anhyd. Na2SO4. After removal of solvent the crude product was purified by column chromatography with silica gel using a mixture of petroleum ether (bp 40−80 °C) and ethyl acetate (4:1) to give 217 mg of 6a (99%).

Characterization Data of Products (6a−6b). 6H-Indolo[2,3 b]quinoline (6a): yield 99%; light-yellow solid; mp 276–280 °C; ¹H NMR (DMSO- d_6 , 400 MHz): δ 11.68 (1H, s), 9.04 (1H, s), 8.25 (1H, d, $J = 7.6$ Hz), 8.09 (1H, dd, $J = 0.8$, 8.0 Hz), 7.96 (1H, d, $J = 8.4$ Hz), 7.69−7.73 (1H, m), 7.45−7.55 (3H, m), 7.24−7.28 (1H, m) ; 13C NMR (DMSO-d₆, 100 MHz): δ 152.8, 146.3, 141.4, 128.6, 128.1, 127.4, 126.9, 123.6, 122.6, 121.7, 120.2, 119.6, 117.8, 111.5, 110.8; IR (neat) ν: 3400, 3131, 2922, 2852, 1609, 1457, 1379, 1261, 1230, 1157, 1071, 1014, 947, 781, 731, 692, 472 cm[−]¹ ; HRMS (ESI) calcd for $C_{15}H_{11}N_2$ (M⁺ + H): 219.0917, found: 219.0913.

11-Methyl-6H-indolo[2,3-b]quinoline (6b): yield 99%; light-yellow solid; mp 260−262 °C; ¹H NMR (DMSO- d_6 , 400 MHz): δ 11.67 $(1H, s)$, 8.31–8.34 $(2H, m)$, 7.94 $(1H, dd, J = 0.8, 8.4 Hz)$, 7.69–7.73 (1H, m), 7.47−7.54 (3H, m), 7.25−7.29 (1H, m) ; 13C NMR $(DMSO-d₆, 100 MHz): \delta$ 152.2, 146.0, 141.3, 138.7, 128.4, 127.4, 127.3, 124.3, 123.6, 123.4, 122.4, 121.0, 119.6, 115.9, 110.7, 14.8; IR (neat) ν: 3781, 3691, 3401, 3159, 3086, 2922, 2856, 1668, 1602, 1453, 1385, 1240, 1062, 1025, 738, 594, 403 cm[−]¹ ; HRMS (ESI) calcd for $C_{16}H_{13}N_2$ (M⁺ + H): 233.1073, found: 233.1078.

General Procedure for Preparing Neocryptolepine (7a) and 11-Methylneocryptolepine (7b). Dimethyl sulfate (150.7 mg, 1.2 equiv) was added to a solution of 6a (0.9954 mmol, 217 mg) in dry acetonitrile (5 mL) under argon and then refluxed for 12 h. On completion, the reaction was quenched with aq solution of K_2CO_3 and extracted with ethyl acetate. The combined organic phases were washed with aq K_2CO_3 and brine and dried over anhyd. Na_2SO_4 . After removal of solvent the crude product was purified by column chromatography with silica gel using mixture of petroleum ether (bp 40−80 °C) and ethyl acetate (20: 1) to give 204 mg of 7a (88%).

Characterization Data of Products (7a and 7b). 5-Methyl-5H-indolo[2,3-b]quinoline (7a): yield 88%; red solid; mp 101−103 $^{\circ}$ C; ¹H NMR (CDCl₃, 400 MHz): δ 8.71 (1H, s), 8.12 (2H, t, J = 6.8 Hz), 7.99 (1H, d, J = 8.0 Hz), 7.69 (1H, m), 7.56−7.60 (1H, m), 7.41−7.47 (2H, m), 7.29 (1H, t, J = 7.6 Hz), 3.99 (3H, s); ¹³C NMR $(CDCl₃, 100 MHz): \delta$ 146.8, 142.8, 128.8, 128.5, 128.0, 127.5, 127.3, 124.1, 122.8, 121.4, 120.4, 119.9, 118.2, 118.0, 108.7, 27.7; IR (neat) ν . 3396, 3054, 2924, 2853, 1724, 1637, 1606, 1574, 1491, 1474, 1430, 1396, 1360, 1321, 1255, 1118, 1019, 787, 744, 600, 476 cm⁻¹; HRMS (ESI) calcd for $C_{16}H_{13}N_2$ (M⁺ + H): 233.1073, found: 233.1066.

5,11-Dimethyl-5H-indolo[2,3-b]quinoline (7b): yield 81%; paleyellow solid; mp 222−224 °C; ¹H NMR (CDCl₃, 400 MHz): δ 8.28 $(1H, d, J = 8.0 Hz)$, 8.23 $(1H, d, J = 8.4 Hz)$, 7.69 $(1H, t, J = 7.2 Hz)$, 7.56 (1H, t, $J = 7.6$ Hz), 7.46 (1H, t, $J = 8.0$ Hz), 7.42 (1H, d, $J = 8.0$ Hz), 7.30 (1H, t, J = 7.6 Hz), 3.08 (3H, s), 3.20 (3H, s); ¹³C NMR $(CDCl₃, 100 MHz): \delta$ 142.7, 130.2, 130.0, 128.5, 128.0, 127.9, 127.3, 124.1, 124.0, 123.5, 122.5, 121.4, 119.8, 108.5, 62.1, 31.9, 14.1; IR (neat) ν: 3407, 2922, 2852, 1742, 1632, 1603, 1460, 1383, 1215, 1155, 1090, 1067, 1025, 758, 667 cm⁻¹; HRMS (ESI) calcd for C₁₇H₁₅N₂ $(M^+ + H)$: 247.1230, found: 247.1234.

■ ASSOCIATED CONTENT

S Supporting Information

Experimental details, analytical data for all new compounds, and X-ray crystallography data of 3j in CIF format. This material is available free of charge via the Internet at http:// pubs.acs.org

■ [AUTHO](http://pubs.acs.org)R INFORMATION

Corresponding Author

*liangym@lzu.edu.cn

■ [ACKNOWLEDG](mailto:liangym@lzu.edu.cn)MENTS

We thank the NSF (NSF-21072080, NSF-20732002) for financial support. We acknowledge National Basic Research Program of China (973 program), 2010CB833203, and also the support by the 111 Project.

■ REFERENCES

(1) Yang, S. W.; Abdel-Kader, M.; Malone, S.; Werkhoven, M. C. M.; Jan, H. W.; Bursuker, I.; Neddermann, K.; Fairchild, C.; Raventos-Suarez, C.; Menendez, A. T.; Lane, K.; Kingston, D. G. I. J. Nat. Prod. 1999, 62, 976. (2) Molina, A.; Vaquero, J. J.; Garcia-Navio, J. L.; Alvarez-Builla, J.; Pascula-Terasa, B.; Gago, F.; Rodrigo, M. M.; Ballestros, M. J. Org. Chem. 1996, 61, 5587−5599.

(3) Guittat, L.; Alberti, P.; Rosu, F.; Van Miert, S.; Thetiot, E.; Pieters, L.; Gabelica, V.; Pauw, D. E.; Ottaviani, A.; Riou, J. F.; Mergny, J. L. Biochimie 2003, 85, 535.

(4) (a) Molina, P.; Alajarin, M.; Vidal, A. J. Chem. Soc., Chem. Commun. 1990, 1277. (b) Molina, P.; Alajarin, M.; Vidal, A.; Sanchez-Andrada, P. J. Org. Chem. 1992, 57, 929.

(5) Shi, C.; Zhang, Q.; Wang, K. K. J. Org. Chem. 1999, 64, 925.

(6) (a) Saito, T.; Ohmori, H.; Furuno, E.; Motoki, S. J. Chem. Soc., Chem. Commun. 1992, 22. (b) Saito, T.; Ohmori, H.; Ohkubo, T.; Motoki, S. J. Chem. Soc., Chem. Commun. 1993, 1802.

(7) Zhang, Q.; Shi, C.; Zhang, H.-R.; Wang, K. K. J. Org. Chem. 2000, 65, 7977.

(8) (a) Molina, P.; Fresneda, P. M.; Delgado, S. Synthesis 1999, 326. (b) Fresneda, P. M.; Molina, P.; Delgado, S. Tetrahedron Lett. 1999, 40, 7275. (c) Alajarin, M.; Molina, P.; Vidal, A. J. Nat. Prod. 1997, 60, 747.

(9) Timari, G.; Soos, T.; Hajos, G. Synlett 1997, 1067.

(10) Vecchione, M. K.; Sun, A. X.; Seidel, D. Chem. Sci. 2011, DOI: 10.1039/c1sc00506e.

(11) During our study of this annulation approach of indoles to $indolo(2,3-b)$ quinolines, a similar approach¹⁰ to neocryptolepine and analogues has been developed by Seidel's group using free indoles and secondary aminobenzaldehydes as coupling partners. However, Siedel's approach is limited to the use of secondary aminobenzaldehydes and the inertness of aminobenzophenones indicates the lack of substrate generality. Moreover, when Siedel's approach was applied to our model substrates, we did not obtain the expected product (see scheme below for inertness of aminobenzophenones to Seidel's approach).

(12) Ali, S.; Zhu, H. T.; Xia, X. F.; Ji, K. G.; Yang, Y. F.; Song, X. R.; Liang., Y. M. Org. Lett. 2011, 13, 2598−2601.

(13) Forrest, T. P.; Dauphinee, G. A.; Deraniyagala, S. A. Can. J. Chem. 1985, 63, 412.

The Journal of Organic Chemistry and the Second Second

(14) Zhang, X.; Campo, M. A.; Yao, T.; Larock, R. C. Org. Lett. 2OO5, 7, 763−766.

(15) Cimanga, K.; De Bruyne, T.; Pieters, L.; Claeys, M.; Vlietinck, A. J. Nat. Prod. 1997, 60, 688.

(16) (a) Peczynska-Czoch, W.; Pognan, F.; Kaczmarek, L.; Boratynski, J. J. Med. Chem. 1994, 37, 3503. (b) Kaczmarek, L.; Balicki, R.; Nantka-Namirski, P.; Peczynska-Czoch, W.; Mordarski, M. Arch. Pharm. (Weinheim, Ger.) 1998, 321, 463.

(17) Forbes, I. T.; Johnson, C. N.; Thompson, M J. Chem. Soc., Perkin Trans. I 1992, 275−281.

(18) Peczynska-Czoch, W; Pognan, F; Kaczmarek, L; Boratyliski, J. J. Med. Chem. 1994, 37, 3503−3510.

(19) Merlic, C. A.; You, Y.; Mclnnes, D. M.; Zechman, A. L.; Miller, M. M.; Deng, Q. Tetrahedron 2001, 57, 5199−5212.

(20) Kothandaraman, P.; Rao, W.; Foo, S. J.; Chan, P. W. H. Angew. Chem., Int. Ed 2010, 49, 1−6.

(21) Goujon, J. Y.; Zammattio, F. O.; Chre´tien, J.; Beaudet, I. Tetrahedron 2004, 60, 4037−4049.

(22) Diedrich, C. L.; Haase, D.; Saak, W.; Christoffers, J. Eur. J. Org. Chem. 2008, 1811−1816.